CGBio (CEO Hyun Seung Yu), specializing in bio regenerative medicine, announced on the 25th the acquisition of a permit for its hyaluronic acid (HA) filler Aileene from the Therapeutic Goods Administration (TGA).

It is the first permit granted for a domestic filler in the country and is the result of CGBio’s years of experience in obtaining overseas licensing. CGBio is currently making substantial investments for the global advance of filler products. The recent acquisition of the permit was driven by CGBio’s aspiration to enter the Australian market, which has the largest cosmetic surgery market among the Oceania nations and eventually to pre-occupy the filler markets throughout the Oceania continent.

Aileene is a representative HA that began its global expansion in 2022, accelerating the company’s export. It currently has a presence in about 31 countries. With this permit acquisition, CGBio plans to showcase the excellence of Aileene in Australia and actively expand its market share. As of 2022, the cosmetic surgery market amounts to about KRW 5 trillion .

For a rapid expansion into the Australian market, CGBio signed a KRW 40 billion supply contract in March with Amore Aesthetics, Australia’s leading aesthetics medical device distributor, for a period of four years prior to the permit acquisition. Hence, CGBio is all set to commence sales and distribution activities immediately using around 300 networks owned by Amore Aesthetics. Accordingly, Aileene is expected to be the nation’s first filler to officially enter the Australian market.

Aileene is the world’s first multi-layered phasic product that combines the benefits of high viscosity monophasic fillers and high elasticity biphasic fillers. It features exceptional voluminous capabilities and cohesiveness, resulting in well-plumped looks. It also minimizes the MOD value to around 2% for higher safety, which means a lesser risk of adverse effects such as swelling and inflammation .

Aileene comes in three distinct types, each tailored to specific viscosity and elasticity levels for application on different areas of the body. Vol#1 is suitable for thin and soft areas such as between the eyes and under the eyes. Vol#2 is designed for areas requiring a plumped look and longer retention such as the cheeks, nasolabial folds and forehead. Vol#3 featuring high viscosity and elasticity is specifically formulated for areas requiring a higher volume such as the nose, forehead and chin.

CGBio CEO Hyun Seung Yu said, “The recent acquisition of a permit for Aileene carries grave significance as it is a historic case where a domestic filler obtains the first-ever permit in the Oceanian cosmetic surgery market,” adding, “We will speed up increasing market share in Australia, which has the largest cosmetic surgery market in Oceania, through active marketing and distribution activities based on the competitive advantages of K-filler.”